Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Specimen Handling 113Magnetic Resonance Spectroscopy 113Cyclophosphamide 106pembrolizumab 82Radiotherapy 79Nivolumab 68Cisplatin 67fludarabine 64Carboplatin 59Biopsy 54Standard of Care 46Radiosurgery 43Gemcitabine 43Paclitaxel 42Dexamethasone 41Rituximab 37Radiation 37Doxorubicin 37Blood Specimen Collection 37Cytarabine 36Bevacizumab 35venetoclax 34fludarabine phosphate 33Surveys and Questionnaires 32Temozolomide 31Radiotherapy, Intensity-Modulated 31Capecitabine 31Practice Guidelines as Topic 28Etoposide 28Oxaliplatin 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Loratadine × 30 days × Clear all
NCT04211259 2026-05-29

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Rutgers, The State University of New Jersey

Phase EARLY_PHASE1 Recruiting
70 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡